Skip to main content

MS Infusion Timing: Why Longer Gaps May Need a Check

By MS Buddy ·

Summarized from Multiple sclerosis (Houndmills, Basingstoke, England), Nov 2026 · PubMed · DOI. AI-generated summary. Not medical advice.

Research by Liza Gelissen, Theo Rispens and 6 colleagues at Amsterdam University Medical Centers, Uppsala University and 1 other institution in the Netherlands and Sweden.

Key Takeaway

In one person with MS, changing natalizumab infusions from every four weeks to every six weeks was followed by low drug levels and antibodies that may make the treatment less effective.

Credibility
Interest
Share:2 min read

What They Found

The person had taken natalizumab for years before switching to a longer gap between infusions. After the switch, the amount of medicine left in their blood just before the next infusion was unexpectedly low. Their body also made increasing amounts of antibodies, which are proteins that can block a medicine or help clear it away. A computer model suggested that falling drug levels may have helped trigger these antibodies. The researchers warned that this cycle could leave less medicine available to control MS and raise the risk of new disease activity.

Who Should Care and Why

This finding matters most to people taking natalizumab on a longer infusion schedule and to the caregivers who help track their care. A longer gap may be convenient, but this case shows why it is worth discussing the plan with your MS care team. Think of drug levels like fuel in a tank: the researchers found that the level was unusually low before the next scheduled refill. Ask your care team whether they need to check how well the treatment is working, especially if you notice new or worsening symptoms. Do not change your infusion schedule on your own; your care team can weigh the possible benefits and risks for you.

Important Considerations

This report describes just one person, so it cannot show how often this happens to others with MS. The computer model suggested a possible reason for the antibody increase, but it could not prove that longer gaps caused it. The report does not show that everyone on a six-week schedule needs a change, so decisions should be made with your MS care team.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in Multiple sclerosis (Houndmills, Basingstoke, England) by et al.. Reproduced from the PubMed record.

We present a natalizumab-treated patient with multiple sclerosis (MS) who developed neutralizing anti-drug antibodies (ADAs) after years of treatment following introduction of extended interval dosing (EID). To gain insight into how this sudden ADA development occurred. A pharmacokinetic model was used to evaluate the relation between natalizumab concentration and ADA production. EID from 4 to 6 weeks resulted in unexpectedly low natalizumab trough concentrations accompanied by increasing ADAs. Modeling suggested ADA production was stimulated by declining natalizumab concentrations. EID may result in increased ADA production, causing ADA-mediated clearance of natalizumab and risking new MS activity.

Trials you could look into

This study looked at a treatment with MS trials currently recruiting or under way.

Listing a trial is not a recommendation. Eligibility is decided by the study team, and your neurologist is the person to ask first.

Explore more research

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Brain outline filled with fine, branching nerve fibers on an off-white background.
In relapsing MS, Mavenclad users' thinking scores rose

11/14/2026

In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.

Read More
Brain outline with connecting fibers between its halves, some subtly lighter than others.
MS brain scans cannot confirm nerve signal failure

11/14/2026

An opinion paper explains why MS brain scans can show tissue loss without proving nerve signal failu

Read More
Two parallel paths: one grows uneven while speech-wave shapes beside it become shorter and fainter.
Voice problems were greater with more disability in MS

11/14/2026

In a study of people with MS, those with greater disability reported more voice problems and vocal f

Read More
Layered paper circles hold faint abstract shapes on a warm neutral background.
Virus blood tests showed past exposure in Brazilian MS

11/15/2026

In 70 people with MS in Brazil, blood tests often showed signs of past viral exposure. Results did n

Read More
Two paper paths meet at an open junction, surrounded by layered shapes in muted colors.
When older adults with MS should stop drugs remains unclear

11/15/2026

A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older

Read More
A simple eye leads to several paths; one reaches an abstract brain-and-spine shape.
Some with first optic nerve inflammation later had MS

11/12/2026

In a study of 601 people in Japan after first optic nerve inflammation, some later had MS. Others ha

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.